Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Michael White

Showing results (61-70 of 284) with videos related to

Pageof 29
Sort By:
The Annals of Pharmacotherapy|October 26, 2002
Amlodipine versus Angiotensin-receptor blockers for nonhypertension indicationsJames S Kalus, C Michael White
Clinical Pharmacokinetics|April 4, 2002
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an updateJessica C Song, C Michael White
Expert Opinion on Pharmacotherapy|August 8, 2019
Pharmacologic considerations in the management of acute coronary syndrome in elderly patientsBrandon K Martinez, C Michael White
JAMA|November 23, 2021
Risk of N-Nitrosodimethylamine (NMDA) Formation With Ranitidine-ReplyC Michael White, Adrian V Hernandez
Journal of Clinical Pharmacology|August 16, 2021
Drugs of Abuse: How Clinical Pharmacology Brings Clarity to the ShadowsAnne N Nafziger, C Michael White
Journal of Clinical Pharmacology|June 13, 2020
Why Your Patients' Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% DangerousC Michael White, Adrian V Hernandez
JAMA|June 28, 2021
Ranitidine and Risk of N-Nitrosodimethylamine (NDMA) FormationC Michael White, Adrian V Hernandez
Journal of Clinical Pharmacology|October 1, 2003
Levosimendan: implications for cliniciansBrian F McBride, C Michael White
Connecticut Medicine|February 10, 2007
A comparison of different protease inhibitors on coronary heart disease riskCraig I Coleman, C Michael White
Connecticut Medicine|May 10, 2007
Renin-angiotensin system inhibitors for prevention of new-onset atrial fibrillationWilliam L Baker, C Michael White
Pageof 29

Showing results (61-70 of 284) with videos related to

Sort By:
Pageof 29
The Annals of Pharmacotherapy|October 26, 2002
Amlodipine versus Angiotensin-receptor blockers for nonhypertension indicationsJames S Kalus, C Michael White
Clinical Pharmacokinetics|April 4, 2002
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an updateJessica C Song, C Michael White
Expert Opinion on Pharmacotherapy|August 8, 2019
Pharmacologic considerations in the management of acute coronary syndrome in elderly patientsBrandon K Martinez, C Michael White
JAMA|November 23, 2021
Risk of N-Nitrosodimethylamine (NMDA) Formation With Ranitidine-ReplyC Michael White, Adrian V Hernandez
Journal of Clinical Pharmacology|August 16, 2021
Drugs of Abuse: How Clinical Pharmacology Brings Clarity to the ShadowsAnne N Nafziger, C Michael White
Journal of Clinical Pharmacology|June 13, 2020
Why Your Patients' Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% DangerousC Michael White, Adrian V Hernandez
JAMA|June 28, 2021
Ranitidine and Risk of N-Nitrosodimethylamine (NDMA) FormationC Michael White, Adrian V Hernandez
Journal of Clinical Pharmacology|October 1, 2003
Levosimendan: implications for cliniciansBrian F McBride, C Michael White
Connecticut Medicine|February 10, 2007
A comparison of different protease inhibitors on coronary heart disease riskCraig I Coleman, C Michael White
Connecticut Medicine|May 10, 2007
Renin-angiotensin system inhibitors for prevention of new-onset atrial fibrillationWilliam L Baker, C Michael White
Pageof 29